BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Pancreatic cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Treatment
483 results:

  • 1. Metformin and pancreatic neuroendocrine tumors: A systematic review and meta-analysis.
    Cigrovski Berkovic M; Coppola A; Sesa V; Mrzljak A; Lai Q
    World J Gastroenterol; 2024 Feb; 30(7):759-769. PubMed ID: 38515954
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Glycolysis-non-canonical glutamine dual-metabolism regulation nanodrug enhanced the phototherapy effect for pancreatic ductal adenocarcinoma treatment.
    Qiao J; Liu S; Huang Y; Zhu X; Xue C; Wang Y; Xiong H; Yao J
    J Colloid Interface Sci; 2024 Jul; 665():477-490. PubMed ID: 38429120
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study.
    Katsuya Y; Yoshida T; Takashima A; Yonemori K; Ohba A; Yazaki S; Yagishita S; Nakahama H; Kobayashi O; Yanagida M; Irino Y; Hamada A; Yamamoto N
    Int J Clin Oncol; 2024 Apr; 29(4):386-397. PubMed ID: 38381163
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. PW06 suppresses cancer cell metastasis in human pancreatic carcinoma MIA PaCa-2 cells via the inhibitions of p-Akt/mtor/NF-κB and MMP2/MMP9 signaling pathways in vitro.
    Huang YP; Yeh CA; Ma YS; Chen PY; Lai KC; Lien JC; Hsieh WT
    Environ Toxicol; 2024 May; 39(5):2768-2781. PubMed ID: 38264921
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Hypoxia upregulating ACSS2 enhances lipid metabolism reprogramming through HMGCS1 mediated PI3K/AKT/mtor pathway to promote the progression of pancreatic neuroendocrine neoplasms.
    Gu D; Ye M; Zhu G; Bai J; Chen J; Yan L; Yu P; Lu F; Hu C; Zhong Y; Liu P; He Q; Tang Q
    J Transl Med; 2024 Jan; 22(1):93. PubMed ID: 38263056
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. pancreatic cancer stem cell-derived exosomal miR-210 mediates macrophage M2 polarization and promotes gemcitabine resistance by targeting FGFRL1.
    Guo Y; Cui J; Liang X; Chen T; Lu C; Peng T
    Int Immunopharmacol; 2024 Jan; 127():111407. PubMed ID: 38134594
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. [Saikosaponin D regulates apoptosis and autophagy of pancreatic cancer Panc-1 cells via Akt/mtor pathway].
    Guan YH; Liu GM; Liu YS; Lan LB; Zheng R; Liu XB
    Zhongguo Zhong Yao Za Zhi; 2023 Oct; 48(19):5278-5284. PubMed ID: 38114117
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Advances in understanding and management of high-grade pancreatic neuroendocrine neoplasm: a comprehensive review.
    Regalla DKR; Deep O; Paluri RK
    Chin Clin Oncol; 2023 Dec; 12(6):67. PubMed ID: 38073310
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. TP53/mtorC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma.
    Yu J; Ling S; Hong J; Zhang L; Zhou W; Yin L; Xu S; Que Q; Wu Y; Zhan Q; Bao J; Xu N; Liu Y; Chen K; Wei X; Liu Z; Feng T; Zhou L; Xie H; Wang S; Liu J; Zheng S; Xu X
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030304
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. A review of functional pancreatic neuroendocrine tumors: Exploring the molecular pathogenesis, diagnosis and treatment.
    Alshareefy Y; Cummins S; Mazzoleni A; Sharma V; Guggilapu S; Leong AWY; Wireko AA
    Medicine (Baltimore); 2023 Nov; 102(46):e36094. PubMed ID: 37986400
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Glutamine synthetase and hepatocellular carcinoma.
    Jiang J; Hu Y; Fang D; Luo J
    Clin Res Hepatol Gastroenterol; 2023 Dec; 47(10):102248. PubMed ID: 37979911
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. AUM302, a novel triple kinase PIM/PI3K/mtor inhibitor, is a potent in vitro pancreatic cancer growth inhibitor.
    Ingle K; LaComb JF; Graves LM; Baines AT; Bialkowska AB
    PLoS One; 2023; 18(11):e0294065. PubMed ID: 37943821
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. SNHG15 promotes gallbladder cancer progression by enhancing the autophagy of tumor cell under nutrition stress.
    Min H; Yang L; Xu X; Geng Y; Liu F; Liu Y
    Cell Cycle; 2023 Oct; 22(19):2130-2141. PubMed ID: 37937948
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
    Sohel M
    Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in pancreatic cancer.
    Kim MJ; Kim HS; Kang HW; Lee DE; Hong WC; Kim JH; Kim M; Cheong JH; Kim HJ; Park JS
    Cells; 2023 Oct; 12(20):. PubMed ID: 37887353
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. pancreatic neuroendocrine tumor progression and resistance to everolimus: the crucial role of NF-kB and STAT3 interplay.
    Vitali E; Valente G; Panzardi A; Laffi A; Zerbi A; Uccella S; Mazziotti G; Lania A
    J Endocrinol Invest; 2024 May; 47(5):1101-1117. PubMed ID: 37882947
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. ALKBH5 enhances lipid metabolism reprogramming by increasing stability of FABP5 to promote pancreatic neuroendocrine neoplasms progression in an m6A-IGF2BP2-dependent manner.
    Chen J; Ye M; Bai J; Gong Z; Yan L; Gu D; Hu C; Lu F; Yu P; Xu L; Wang Y; Tian Y; Tang Q
    J Transl Med; 2023 Oct; 21(1):741. PubMed ID: 37858219
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Chloroxine inhibits pancreatic cancer progression through targeted antagonization of the PI3K/AKT/mtor signaling pathway.
    Lin M; Xiao Y; Dai Y; Mao Y; Xu L; Zhang Q; Chen Z
    Clin Transl Oncol; 2024 Apr; 26(4):951-965. PubMed ID: 37848695
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Efficacy and safety of abemaciclib alone and with PI3K/mtor inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial.
    Chiorean EG; Picozzi V; Li CP; Peeters M; Maurel J; Singh J; Golan T; Blanc JF; Chapman SC; Hussain AM; Johnston EL; Hochster HS
    Cancer Med; 2023 Oct; 12(20):20353-20364. PubMed ID: 37840530
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Study the Anticancer Properties of Thymol-Loaded PEGylated Bovine Serum Albumin Nanoparticles Conjugated with Folic Acid.
    Al-Salih MYA; Pouresmaeil V; Davoodi-Dehaghani F; Haghighi HN; Tabrizi MH
    Chem Biodivers; 2023 Nov; 20(11):e202301122. PubMed ID: 37823866
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 25.